Bio-Connect

RBP4 (human) Competitive ELISA Kit

Research Use Only
AG-45A-0010YEK
AdipoGen Life Sciences
Product group Assays
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    RBP4 (human) Competitive ELISA Kit
  • Delivery Days Customer
    10
  • Applications
    ELISA
  • Assay Detection Range
    0.001 to 5microg/ml
  • Assay Sensitivity
    1ng/ml
  • Assay Specificity
    Detects human RBP4. Does not cross-react with human adiponectin, human resistin or human RELM-beta.
  • Certification
    Research Use Only
  • Scientific Description
    ELISA Assay. Detects human RBP4. Does not cross-react with human adiponectin, human resistin or human RELM-beta. Colorimetric assay. Sample Types: Cell Culture Supernatant, Plasma, Serum, Urine. Range: 0.001 to 5microg/ml. Sensitivity: 1ng/ml. Retinol binding protein 4 (RBP4; RBP) is a 21kDa secreted protein, a member of the lipocalin family and is known as the primary transporter of retinol (vitamin A) to tissues. A recent report revealed RBP4 as an adipokine linking glucose transporter 4 (GLUT4) suppression in adipose tissue to insulin. Elevated human and mouse serum RBP4 levels are associated with insulin resistance and its severity, obesity and certain components of metabolic syndrome. Furthermore, human serum RBP4 levels are closely related to renal function and recent studies have shown an association between serum RBP4 levels and urinary albumin excretion. The urinary RBP4 concentration may be a valuable marker for both, insulin resistance and microalbuminuria in insulin-resistant subjects. - Retinol binding protein 4 (RBP4; RBP) is a 21kDa secreted protein, a member of the lipocalin family and is known as the primary transporter of retinol (vitamin A) to tissues. A recent report revealed RBP4 as an adipokine linking glucose transporter 4 (GLUT4) suppression in adipose tissue to insulin. Elevated human and mouse serum RBP4 levels are associated with insulin resistance and its severity, obesity and certain components of metabolic syndrome. Furthermore, human serum RBP4 levels are closely related to renal function and recent studies have shown an association between serum RBP4 levels and urinary albumin excretion. The urinary RBP4 concentration may be a valuable marker for both, insulin resistance and microalbuminuria in insulin-resistant subjects.
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    41116158

References

  • Retinol-binding protein 4 in human obesity: J. Janke, et al.; Diabetes 55, 2805 (2006)
  • Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes: Y.M. Cho, et al.; Diabetes Care 29, 2457 (2006)
  • Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents: D.C. Lee et al.; Metab. Clin. Exp. 56, 327 (2007)
  • High circulating retinol-binding protein 4 is associated with elevated liver fat, but not with total-, subcutaneous-, visceral-, or intramyocellular fat in humans: N. Stefan et al.; Diabetes Care 30, 1173 (2007)
  • Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes: A. Cabre, et al.; J. Intern. Med. 262, 496 (2007)
  • Visceral adiposity is associated with serum retinol binding protein-4 levels in healthy women: J.W. Lee, et al.; Obesity (Silver Spring) 15, 2225 (2007)
  • Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects: response to Broch et al: N. Stefan, et al.; Diabetes Care 30, e91 (2007)
  • Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor: M. Promintzer, et al.; J. Clin. Endocrinol. Metab. 92, 4306 (2007)
  • Serum levels of adipokine retinol-binding protein-4 in relation to renal function: M. Ziegelmeier, et al.; Diabetes Care 30, 2588 (2007)
  • Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease: J.A. Seo, et al.; Clin. Endocrinol. (Oxf ) 68, 555 (2008)